https://novapharmanews.com/us/news/adial-pharmaceuticals-cdo-adds-equity-after-azora-merger 2026-06-18T20:18:10.298Z NovaPharmaNews en 2026-06-18T20:18:10.298Z Adial Pharmaceuticals Completes Azora Merger, Expands Ulcerative Colitis Pipeline https://novapharmanews.com/uploads/articles/adial-pharmaceuticals-cdo-adds-equity-after-azora-merger.webp Adial Pharmaceuticals Completes Azora Merger, Expands Ulcerative Colitis Pipeline https://novapharmanews.com/eu/news/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now 2026-06-17T07:41:18.208Z NovaPharmaNews en 2026-06-17T04:37:32.376Z EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/uploads/articles/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now.webp EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/us/news/biotechs-coming-of-age-ai-capital-efficiency-china 2026-06-18T21:36:20.803Z NovaPharmaNews en 2026-06-17T04:21:05.361Z Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/uploads/articles/biotechs-coming-of-age-ai-capital-efficiency-china.webp Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/us/news/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test 2026-06-18T19:46:36.736Z NovaPharmaNews en 2026-06-16T22:28:18.759Z Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test EDG-7500, hypertrophic cardiomyopathy, obstructive HCM, cardiac diastolic dysfunction https://novapharmanews.com/uploads/articles/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test.webp Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test